177 related articles for article (PubMed ID: 12394802)
1. Weight loss and survival in HIV-positive patients in the era of highly active antiretroviral therapy.
Tang AM; Forrester J; Spiegelman D; Knox TA; Tchetgen E; Gorbach SL
J Acquir Immune Defic Syndr; 2002 Oct; 31(2):230-6. PubMed ID: 12394802
[TBL] [Abstract][Full Text] [Related]
2. Increasing risk of 5% or greater unintentional weight loss in a cohort of HIV-infected patients, 1995 to 2003.
Tang AM; Jacobson DL; Spiegelman D; Knox TA; Wanke C
J Acquir Immune Defic Syndr; 2005 Sep; 40(1):70-6. PubMed ID: 16123685
[TBL] [Abstract][Full Text] [Related]
3. Weight loss, wasting, and survival in HIV-positive patients: current strategies.
Tang AM
AIDS Read; 2003 Dec; 13(12 Suppl):S23-7. PubMed ID: 14959696
[TBL] [Abstract][Full Text] [Related]
4. Phase angle from bioelectrical impedance analysis remains an independent predictive marker in HIV-infected patients in the era of highly active antiretroviral treatment.
Schwenk A; Beisenherz A; Römer K; Kremer G; Salzberger B; Elia M
Am J Clin Nutr; 2000 Aug; 72(2):496-501. PubMed ID: 10919947
[TBL] [Abstract][Full Text] [Related]
5. Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy.
Wanke CA; Silva M; Knox TA; Forrester J; Speigelman D; Gorbach SL
Clin Infect Dis; 2000 Sep; 31(3):803-5. PubMed ID: 11017833
[TBL] [Abstract][Full Text] [Related]
6. Treatment of HIV-associated wasting with recombinant human growth hormone: monitoring of body composition changes by bioelectrical impedance analysis (BIA).
Jäger H; Knechten H; Moll A; Weitner L; Fischer H; Schmitt-Rau K
Eur J Med Res; 2002 Mar; 7(3):103-8. PubMed ID: 11953280
[TBL] [Abstract][Full Text] [Related]
7. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
[TBL] [Abstract][Full Text] [Related]
8. Increase in body cell mass and decrease in wasting are associated with increasing potency of antiretroviral therapy for HIV infection.
Ferrando SJ; Rabkin JG; Lin SH; McElhiney M
AIDS Patient Care STDS; 2005 Apr; 19(4):216-23. PubMed ID: 15857193
[TBL] [Abstract][Full Text] [Related]
9. Nutrition and HIV infection: review of weight loss and wasting in the era of highly active antiretroviral therapy from the nutrition for healthy living cohort.
Mangili A; Murman DH; Zampini AM; Wanke CA
Clin Infect Dis; 2006 Mar; 42(6):836-42. PubMed ID: 16477562
[TBL] [Abstract][Full Text] [Related]
10. Impact of HAART on survival, weight gain and resting energy expenditure in HIV-1-infected children in India.
Banerjee T; Pensi T; Banerjee D; Grover G
Ann Trop Paediatr; 2010; 30(1):27-37. PubMed ID: 20196931
[TBL] [Abstract][Full Text] [Related]
11. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
[TBL] [Abstract][Full Text] [Related]
12. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
[TBL] [Abstract][Full Text] [Related]
13. Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy.
Kohli R; Lo Y; Howard AA; Buono D; Floris-Moore M; Klein RS; Schoenbaum EE
Clin Infect Dis; 2005 Sep; 41(6):864-72. PubMed ID: 16107987
[TBL] [Abstract][Full Text] [Related]
14. CD4 percentage is an independent predictor of survival in patients starting antiretroviral therapy with absolute CD4 cell counts between 200 and 350 cells/microL.
Moore DM; Hogg RS; Yip B; Craib K; Wood E; Montaner JS
HIV Med; 2006 Sep; 7(6):383-8. PubMed ID: 16903983
[TBL] [Abstract][Full Text] [Related]
15. HIV-related wasting in HIV-infected drug users in the era of highly active antiretroviral therapy.
Campa A; Yang Z; Lai S; Xue L; Phillips JC; Sales S; Page JB; Baum MK
Clin Infect Dis; 2005 Oct; 41(8):1179-85. PubMed ID: 16163638
[TBL] [Abstract][Full Text] [Related]
16. Antiretroviral therapy affects the composition of weight loss in HIV infection: implications for clinical nutrition.
Maia BS; Engelson ES; Wang J; Kotler DP
Clin Nutr; 2005 Dec; 24(6):971-8. PubMed ID: 16095765
[TBL] [Abstract][Full Text] [Related]
17. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
[TBL] [Abstract][Full Text] [Related]
18. Predictors of early mortality in a cohort of HIV-infected children receiving high active antiretroviral treatment in public hospitals in Ethiopia.
Ebissa G; Deyessa N; Biadgilign S
AIDS Care; 2015; 27(6):723-30. PubMed ID: 25599414
[TBL] [Abstract][Full Text] [Related]
19. Understanding the role of HIV load in determining weight change in the era of highly active antiretroviral therapy.
Mwamburi DM; Wilson IB; Jacobson DL; Spiegelman D; Gorbach SL; Knox TA; Wanke CA
Clin Infect Dis; 2005 Jan; 40(1):167-73. PubMed ID: 15614708
[TBL] [Abstract][Full Text] [Related]
20. The impact of malnutrition on survival and the CD4 count response in HIV-infected patients starting antiretroviral therapy.
Paton NI; Sangeetha S; Earnest A; Bellamy R
HIV Med; 2006 Jul; 7(5):323-30. PubMed ID: 16945078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
